Actinium Pharmaceuticals (NYSE:ATNM) Earns Buy Rating from HC Wainwright

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 230.58% from the company’s current price.

Separately, Stephens reissued an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Trading Up 1.7 %

NYSE:ATNM opened at $1.21 on Tuesday. The firm has a market cap of $37.75 million, a P/E ratio of -0.87 and a beta of 0.10. The stock has a 50 day moving average of $1.20 and a two-hundred day moving average of $1.46. Actinium Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ATNM. Squarepoint Ops LLC increased its stake in Actinium Pharmaceuticals by 25.4% in the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after purchasing an additional 37,159 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in Actinium Pharmaceuticals by 49.5% in the fourth quarter. Nuveen Asset Management LLC now owns 148,560 shares of the company’s stock valued at $187,000 after acquiring an additional 49,214 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of Actinium Pharmaceuticals by 413.6% during the fourth quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock worth $155,000 after purchasing an additional 99,158 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Actinium Pharmaceuticals by 76.6% in the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after purchasing an additional 34,176 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of Actinium Pharmaceuticals by 4.9% in the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock valued at $317,000 after purchasing an additional 11,812 shares during the period. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).